Stabilization of measles virus for vaccine formulation.

Stabilization of measles virus for vaccine formulation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Stabilization of measles virus for vaccine formulation. Abstract Text:

An attenuated live measles virus (MV) was characterized by several biophysical methods as a function of temperature and pH. Following a method developed previously, the resultant light scattering and spectroscopic data were synthesized into an empirical phase diagram that visually and simultaneously represents the entire data set. Using this empirically-based phase diagram, screening assays were developed to identify potential vaccine stabilizers. Various compounds are shown by these assays to inhibit the temperature-induced aggregation of viral particles, and also to protect the integrity of the viral envelope. Accelerated stability assays show that, upon thermal challenge, MV formulated with these excipients retains its infectivity to a significant extent. Thus, the enhanced physical stability produced by this method is shown to protect the biological activity of this important but labile vaccine.

Stabilization of measles virus for vaccine formulation. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Stabilization of measles virus for vaccine formulation. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Human vaccines

VOLUME: 4

Page Numbers: 350-9

Journal Abbreviation:

ISSN: 1554-8619

DAY: 7

MONTH: 09

YEAR: 2008

Stabilization of measles virus for vaccine formulation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101265291

Stabilization of measles virus for vaccine formulation. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Stabilization of measles virus for vaccine formulation. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Stabilization of measles virus for vaccine formulation.

AFFILIATION: Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hum Vaccin

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Stabilization of measles virus for vaccine formulation Related Publications

• A Review of: Vaccine Adjuvants and Delivery Systems.
• A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams.
• A network-based analysis of polyanion-binding proteins utilizing human protein arrays.
• A network-based analysis of polyanion-binding proteins utilizing yeast protein arrays.
• A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.
• A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine.
• Conformational flexibility, hydration and state parameter fluctuations of fibroblast growth factor-10: effects of ligand binding.
• Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants.
• Immunoglobulin dynamics, conformational fluctuations, and nonlinear elasticity and their effects on stability.
• Intravenous cocaine self-administration: individual differences in male and female C57BL/6J mice.
• Linked outbreaks of hepatitis A in homosexual men and in food service patrons and employees.
• Pandemic influenza preparedness and community resiliency.
• Periadolescent nicotine exposure reduces cocaine reward in adult mice.
• Physical characterization of clostridium difficile toxins and toxoids: effect of the formaldehyde crosslinking on thermal stability.
• Physical stabilization of norwalk virus-like particles.
• Positions of authority may equal lawsuits.
• Preformulation studies of Clostridium difficile toxoids A and B.
• Side effects of diphtheria-tetanus toxoid in adults.
• Spectroscopic methods for the physical characterization and formulation of nonviral gene delivery systems.
• Stabilization of measles virus for vaccine formulation.
• Stabilization of proteins by recombinant human gelatins.
• The analysis of protein pharmaceuticals: near future advances.
• The complex inter-relationships between protein flexibility and stability.
• The interaction of heparin/polyanions with bovine, porcine, and human growth hormone.
• The structure, stability, and complex behavior of recombinant human gelatins.
• pH sensitivity of type III secretion system tip proteins.